These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1169 related articles for article (PubMed ID: 31899205)

  • 1. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
    Dai W; Xu L; Yu X; Zhang G; Guo H; Liu H; Song G; Weng S; Dong L; Zhu J; Liu T; Guo C; Shen X
    J Hepatol; 2020 May; 72(5):909-923. PubMed ID: 31899205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PPARδ Reprograms Glutamine Metabolism in Sorafenib-Resistant HCC.
    Kim MJ; Choi YK; Park SY; Jang SY; Lee JY; Ham HJ; Kim BG; Jeon HJ; Kim JH; Kim JG; Lee IK; Park KG
    Mol Cancer Res; 2017 Sep; 15(9):1230-1242. PubMed ID: 28584024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis.
    Ding Z; Ericksen RE; Escande-Beillard N; Lee QY; Loh A; Denil S; Steckel M; Haegebarth A; Wai Ho TS; Chow P; Toh HC; Reversade B; Gruenewald S; Han W
    J Hepatol; 2020 Apr; 72(4):725-735. PubMed ID: 31726117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxoglutarate dehydrogenase-like inhibits the progression of hepatocellular carcinoma by inducing DNA damage through non-canonical function.
    Jiang X; Peng J; Xie Y; Xu Y; Liu Q; Cheng C; Yan P; Xu S; Wang Y; Zhang L; Li H; Li Y; Li B; Han J; Yu D
    Cell Death Differ; 2023 Aug; 30(8):1931-1942. PubMed ID: 37419985
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Jiao Y; Li Y; Fu Z; Hou L; Chen Q; Cai Y; Jiang P; He M; Yang Z
    Dis Markers; 2019; 2019():9037131. PubMed ID: 31781311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PMPCB Silencing Sensitizes HCC Tumor Cells to Sorafenib Therapy.
    Zheng JF; He S; Zeng Z; Gu X; Cai L; Qi G
    Mol Ther; 2019 Oct; 27(10):1784-1795. PubMed ID: 31337603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel Oxoglutarate Dehydrogenase-Like Mediated miR-214/TWIST1 Negative Feedback Loop Inhibits Pancreatic Cancer Growth and Metastasis.
    Liu Y; Meng F; Wang J; Liu M; Yang G; Song R; Zheng T; Liang Y; Zhang S; Yin D; Wang J; Yang H; Pan S; Sun B; Han J; Sun J; Lan Y; Wang Y; Liu X; Zhu M; Cui Y; Zhang B; Wu D; Liang S; Liu Y; Song X; Lu Z; Yang J; Li M; Liu L
    Clin Cancer Res; 2019 Sep; 25(17):5407-5421. PubMed ID: 31175094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA LEF1-AS1 silencing diminishes EZH2 expression to delay hepatocellular carcinoma development by impairing CEBPB-interaction with CDCA7.
    Gao J; Dai C; Yu X; Yin XB; Zhou F
    Cell Cycle; 2020 Apr; 19(8):870-883. PubMed ID: 32178558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased Expression of Fructose-1,6-bisphosphatase Associates with Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma.
    Hirata H; Sugimachi K; Komatsu H; Ueda M; Masuda T; Uchi R; Sakimura S; Nambara S; Saito T; Shinden Y; Iguchi T; Eguchi H; Ito S; Terashima K; Sakamoto K; Hirakawa M; Honda H; Mimori K
    Cancer Res; 2016 Jun; 76(11):3265-76. PubMed ID: 27197151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zinc finger protein 703 induces EMT and sorafenib resistance in hepatocellular carcinoma by transactivating CLDN4 expression.
    Wang H; Xu H; Ma F; Zhan M; Yang X; Hua S; Li W; Li Y; Lu L
    Cell Death Dis; 2020 Apr; 11(4):225. PubMed ID: 32269215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deficiency in SLC25A15, a hypoxia-responsive gene, promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
    Zhang Q; Wei T; Jin W; Yan L; Shi L; Zhu S; Bai Y; Zeng Y; Yin Z; Yang J; Zhang W; Wu M; Zhang Y; Peng G; Roessler S; Liu L
    J Hepatol; 2024 Feb; 80(2):293-308. PubMed ID: 38450598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting ODC1 inhibits tumor growth through reduction of lipid metabolism in human hepatocellular carcinoma.
    Choi Y; Oh ST; Won MA; Choi KM; Ko MJ; Seo D; Jeon TW; Baik IH; Ye SK; Park KU; Park IC; Jang BC; Seo JY; Lee YH
    Biochem Biophys Res Commun; 2016 Sep; 478(4):1674-81. PubMed ID: 27592554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GOT2 Silencing Promotes Reprogramming of Glutamine Metabolism and Sensitizes Hepatocellular Carcinoma to Glutaminase Inhibitors.
    Li Y; Li B; Xu Y; Qian L; Xu T; Meng G; Li H; Wang Y; Zhang L; Jiang X; Liu Q; Xie Y; Cheng C; Sun B; Yu D
    Cancer Res; 2022 Sep; 82(18):3223-3235. PubMed ID: 35895805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target.
    Chen H; Wong CC; Liu D; Go MYY; Wu B; Peng S; Kuang M; Wong N; Yu J
    Theranostics; 2019; 9(18):5246-5260. PubMed ID: 31410213
    [No Abstract]   [Full Text] [Related]  

  • 18. OGDHL is a modifier of AKT-dependent signaling and NF-κB function.
    Sen T; Sen N; Noordhuis MG; Ravi R; Wu TC; Ha PK; Sidransky D; Hoque MO
    PLoS One; 2012; 7(11):e48770. PubMed ID: 23152800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of ACADM-Mediated Fatty Acid Oxidation Promotes Hepatocellular Carcinoma via Aberrant CAV1/SREBP1 Signaling.
    Ma APY; Yeung CLS; Tey SK; Mao X; Wong SWK; Ng TH; Ko FCF; Kwong EML; Tang AHN; Ng IO; Cai SH; Yun JP; Yam JWP
    Cancer Res; 2021 Jul; 81(13):3679-3692. PubMed ID: 33975883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silencing
    Zhu Q; Ren H; Li X; Qian B; Fan S; Hu F; Xu L; Zhai B
    Aging (Albany NY); 2020 Nov; 12(22):22975-23003. PubMed ID: 33203790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.